Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Lineage Cell Therapeutics's price to book ratio was 4.6× on Nov 11, 2026, against 18.4× a year earlier. Over the last 5 years it ranged from 1.3× to 18.4×, with a median of 3.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.6× | −12.8 |
| 2025 | Dec 31, 2025 | 17.5× | +16.0 |
| 2024 | Dec 31, 2024 | 1.4× | −1.4 |
| 2023 | Dec 29, 2023 | 2.8× | +0.3 |
| 2022 | Dec 30, 2022 | 2.5× | −0.9 |
| 2021 | Dec 31, 2021 | 3.4× | +0.5 |
| 2020 | Dec 31, 2020 | 2.9× | +1.8 |
| 2019 | Dec 31, 2019 | 1.1× | +0.5 |
| 2018 | Dec 31, 2018 | 0.7× | −0.6 |
| 2017 | Dec 29, 2017 | 1.3× | −1.9 |
| 2016 | Dec 30, 2016 | 3.1× | −22.7 |
| 2015 | Dec 31, 2015 | 25.8× | +2.6 |
| 2014 | Dec 31, 2014 | 23.2× | +7.7 |
| 2013 | Dec 31, 2013 | 15.5× | +6.4 |
| 2012 | Dec 31, 2012 | 9.1× | +0.7 |
| 2011 | Dec 30, 2011 | 8.5× | – |
See a number that looks wrong?